ClinicalTrials.gg
RecruitingNCT07881874Updated Oct 22, 2026

This Study is the Clinical Validation Study for Validation for the Digital Pathology System 'SGi 1.0 + EPW 1.0 + Compatible Clinical Displays'

An observational study in Pathological Processes, sponsored by Philips Digital & Computational Pathology. Recruiting at 2 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Philips Digital & Computational Pathology (part of Philips) · Observational

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 20, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
470
Sex
All
01

Study summary

The primary objective of this study is to show safety and effectiveness of the investigational device for In Vitro Diagnostic (IVD) use as an aid to the pathologist to view, review and diagnose digital images of surgical pathology slides.

02

Conditions studied

  • Pathological Processes

Browse trials for

03

In context

Pathologic Processes

124 studies on the registry are indexed under Pathologic Processes; 28 are open to participants now.

This study's planned enrollment of 470 is above the median of 182 across 29 observational studies indexed under Pathologic Processes.

Browse Pathologic Processes studies →

Lead sponsor

Philips Digital & Computational Pathology is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Probability sample

Study population

Surgical Pathology cases are selected according pre-specified list consisting of consecutive cases from the archive with pre-specified organs and subtypes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All hematoxylin and eosin (H\&E), immunohistochemistry (IHC) and special stains glass coverslipped slide or slides, with human tissue obtained via surgical pathology of original case are available;
  • Original sign-out diagnosis is available;
  • Relevant clinical information that was available to the sign-out pathologist in the pathology request form is available;
  • Cases are at least one year since accessioning;

Exclusion criteria

Exclusion Criteria:

  • Cases, including sent out cases, for which the selected (representative) H\&E, IHC or special stains slide used for the original sign-out diagnosis is no longer available at the site.
  • Cases for which the control slides for IHC and special stains are not available.
  • The selected slide or slides for the main diagnosis and the control slide(s) do not fulfill the quality checks according to general clinical practice.
  • Selected (representative) slides contain indelible markings.
  • Selected (representative) slides with damaged tissue.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
470 participants (estimated)
Patient registry
No

Groups and cohorts

  • Surgical pathology cases

    Cases will be selected from the sites Laboratory Information Systems using the in- and exclusion criteria.

    Diagnostic Test: Digital pathology system

Interventions

  • Diagnostic testDigital pathology system

    Surgical pathology slides are scanned with a digital pathology scanner after which they are viewed by a pathologist on a digital pathology viewer. It is the task of the pathologist to define a diagnosis based on these images.

06

What researchers measure

Primary outcomes

  1. Major Discordance Rate

    The primary endpoint was the difference in major discordance rates between Manual Optical (MO) and Manual Digital (MD). MO is defined as reading by using optical microscope whereas MD is defined as reading by using the digital pathology system. MO major discordance rate is defined as the proportion of major discordances between the MO diagnosis and the main diagnosis from the total number of readings. MD major discordance rate is defined as the proportion of major discordances between the MD diagnosis and the main diagnosis from the total number of readings.

    Time frame: 6 months

Secondary outcomes

  1. MD major discordance rate

    • Explore the MD major discordance rate for individual organs, subtypes and pathologists

    Time frame: 6 months

  2. MO major discordance rate

    Explore the MO major discordance rate for individual organs, subtypes and pathologists;

    Time frame: 6 months

  3. inter-pathologist major discordance rate

    Explore the inter-pathologist major discordance rate.

    Time frame: 6 months

07

Study locations

2 of 2 sites recruiting
08

Updates

2 registry updates since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 20, 2026
Show all 2 updates
  1. Oct 22, 2026
    Minor edits only
    + 1 other change: description
  2. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07881874
Responsible party
Sponsor
First posted
Oct 20, 2026
Start date
Aug 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Oct 22, 2026
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion